Booking a summer holiday often means checking passports, flights and accommodation, but for many people living with inflammatory bowel disease (IBD, a term covering Crohn’s disease and ulcerative colitis), it also means checking the infusion calendar. Biologic infusions are usually scheduled every four to eight weeks, and a two-week holiday can easily fall across one of those dates. Getting this wrong is not just inconvenient; it can affect how well the treatment keeps inflammation under control.
What are biologic infusions?
Biologics are medicines made from living cells that target specific parts of the immune system involved in IBD. Drugs such as infliximab and vedolizumab are given by infusion, meaning they are delivered directly into a vein over one to two hours in a clinic or infusion unit. Unlike tablets taken daily, infusions are given at set intervals, and the gap between doses is carefully calculated so that enough of the drug remains active in the body to keep inflammation suppressed between visits.
Why consistent timing matters for gut inflammation
Biologics work by blocking specific inflammatory signals, such as tumour necrosis factor (TNF, a protein that drives inflammation) or by stopping certain immune cells from migrating into the gut lining. The level of drug in the bloodstream naturally falls between infusions. If a dose is delayed significantly, drug levels can drop low enough for inflammatory activity to pick up again, and in some cases this can lead to the immune system producing antibodies against the biologic, reducing how well it works even after treatment resumes. This is why timing is not simply administrative; it is part of how the treatment maintains its effect.
Key considerations for summer travel
Scheduling around holidays
The most reliable approach is to plan holiday dates around the infusion schedule rather than the other way round. Most IBD teams can shift an infusion by a few days either way without any meaningful loss of effect, but this needs to be discussed in advance rather than assumed. Contacting the IBD nurse specialist or infusion unit as soon as travel dates are known allows enough time to rearrange appointments or confirm that the existing schedule will not clash.
Travelling with infusion appointments abroad
For longer trips, it may be possible to arrange an infusion at a hospital or clinic at the destination, particularly within some healthcare systems that support reciprocal care arrangements. This usually requires a letter from the prescribing team confirming the diagnosis, current treatment, dosing schedule and any relevant blood results. Arrangements like this take time to set up, so they are best started several weeks before departure rather than close to the trip.
Heat, hydration and medication storage
Although infusions themselves are given in a clinical setting, many people on biologics also carry other medications, such as steroids or supportive treatments, that need to be kept within a certain temperature range. Hot climates and car journeys can cause medication to overheat if left in luggage or direct sunlight. Hydration also matters more in warm weather, since dehydration can worsen general fatigue and make it harder to distinguish normal travel tiredness from early signs of a flare.
Recognising symptoms versus flare
Travel itself can cause symptoms that overlap with IBD, including changes in bowel habit from altered diet, disrupted sleep, or travel-related stomach upset. Not every symptom during a holiday means the underlying disease is becoming active again. Persistent blood in the stool, ongoing abdominal pain, fever, or symptoms that do not settle after a few days are more likely to need medical assessment, whereas mild, short-lived changes are common in anyone travelling, regardless of IBD.
It is worth remembering that biologic infusions are one part of a broader treatment plan, and decisions about timing, delays, or missed doses should always involve the prescribing team. Diet, rest and stress management can support general wellbeing around travel, but they do not replace the immune-modulating effect of the biologic itself.
Practical Takeaways
- Share holiday dates with the IBD team as early as possible, ideally when booking travel rather than close to departure.
- Ask whether an infusion date can be safely adjusted rather than assuming it can be moved without checking.
- If travelling for an extended period, ask about arranging an infusion abroad and request supporting documentation in good time.
- Keep a written summary of diagnosis, current treatment and recent blood tests when travelling internationally.
- Store any accompanying medication according to its instructions, away from heat and direct sunlight.
- Monitor symptoms calmly during travel, and seek medical advice if symptoms are severe, persistent or include bleeding.
Conclusion
Biologic infusions are designed to work on a steady rhythm, and summer travel does not need to disrupt that rhythm if it is planned for in advance. Small adjustments, made early and in partnership with the IBD team, generally allow both treatment stability and holiday plans to be maintained together. Symptoms that appear during travel are not automatically a sign of worsening disease, but they are worth monitoring rather than ignoring. Long-term control of IBD depends less on any single holiday and more on the consistency of treatment over time, which is best protected by communication with the clinical team rather than guesswork.
References
- Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987-995. doi:10.1111/j.1365-2036.2011.04612.x
- Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(S3):S39-S50. doi:10.1002/jcph.374
- Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827-834. doi:10.1053/j.gastro.2017.07.032
- Papamichael K, Cheifetz AS. Therapeutic drug monitoring in IBD: the new standard of care. J Crohns Colitis. 2019;13(7):833-834. doi:10.1093/ecco-jcc/jjz039
- Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711-721. doi:10.1056/NEJMoa1215739
- Ben-Horin S, Vande Casteele N, Schreiber S, Laharie D. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685-1696. doi:10.1016/j.cgh.2016.05.023
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.